TAKHZYRO is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in people 12 years of age and older. It is not known if TAKHZYRO is safe and effective in children under 12 years of age.

REIMAGINE YOUR LIFE WITH FEWER ATTACKS

People taking TAKHZYRO had attacks less often in a clinical study

NUMBER OF ATTACKS ON AVERAGE OVER 6.5 MONTHS (26 WEEKS)

Visual comparison of placebo versus TAKHZYRO. On average, people taking placebo had 13 attacks versus 2 attacks for people taking TAKHZYRO 300 mg every 2 weeks.

In the 26-week clinical study, which included 125 people with HAE, people taking TAKHZYRO every 2 weeks also had 83% fewer moderate or severe attacks and 87% fewer attacks that needed acute treatment, compared with placebo.

SELECT IMPORTANT SAFETY INFORMATION

TAKHZYRO may cause serious side effects, including allergic reactions. Call your healthcare provider or get emergency help right away if you have any of the following symptoms:

  • wheezing
  • difficulty breathing
  • chest tightness
  • fast heartbeat
  • faintness
  • rash
  • hives

Many people in the study had zero attacks

In a later analysis of the last
4 months of the clinical study

Nearly 8 out of 10 patients had zero attacks WITH TAKHZYRO 300 MG EVERY 2 WEEKS

  • After taking TAKHZYRO 300 mg every 2 weeks for 2.5 months (10 weeks), 77% of people had zero attacks for the last 4 months of the study, compared with 3% of people taking placebo
  • Over the entire 6.5-month study, 44% of people taking TAKHZYRO 300 mg every 2 weeks had zero attacks, compared with 2% of people taking placebo
  • Although not the main focus of the study, these results support its primary findings. The study was not designed in advance to measure the percentage of attack-free patients during the last 4 months of the study

Patients were also studied taking TAKHZYRO every 4 weeks.

Additional results

SELECT IMPORTANT SAFETY INFORMATION

The most common side effects seen with TAKHZYRO were injection site reactions (pain, redness, and bruising), upper respiratory infection, and headache.

These are not all the possible side effects of TAKHZYRO. For more information, ask your healthcare provider or pharmacist. You may report side effects to the FDA at 1–800–FDA–1088.

Studied in more people than any other preventive HAE treatment

TAKHZYRO helped prevent HAE attacks:

  • Whether previous attacks were frequent or infrequent
  • Whether or not people had a history of throat attacks
  • Regardless of whether preventive therapy had been used before

After completing the initial clinical study, 97% of people in the TAKHZYRO study groups decided to enroll in an ongoing, longer study designed to monitor safety.

What could TAKHZYRO do for you?
Talk to your healthcare provider today.

TAKHZYRO safety information

TAKHZYRO may cause serious side effects, including allergic reactions. Call your healthcare provider or get emergency help right away if you have symptoms of an allergic reaction.

Injection site reactions were the most common side effects of TAKHZYRO

Most common side effects in the clinical study TAKHZYRO
(84 patients)*
Placebo
(41 patients)
Injection site reactions 52% 34%
  • Pain
43% 29%
  • Redness
10% 2%
  • Bruising
7% 0%
Upper respiratory infection 29% 32%
Headache 21% 22%
Rash 7% 5%
Muscle pain 5% 0%
Dizziness 6% 0%
Diarrhea 5% 5%

*Includes all patients treated with TAKHZYRO (300 mg every 2 weeks, 300 mg every 4 weeks, or 150 mg every 4 weeks) in the clinical study.

WHAT IS TAKHZYRO?

TAKHZYRO is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in people 12 years of age and older.

It is not known if TAKHZYRO is safe and effective in children under 12 years of age.

IMPORTANT SAFETY INFORMATION

TAKHZYRO may cause serious side effects, including allergic reactions. Call your healthcare provider or get emergency help right away if you have any of the following symptoms:

  • wheezing
  • difficulty breathing
  • chest tightness
  • fast heartbeat
  • faintness
  • rash
  • hives

The most common side effects seen with TAKHZYRO were injection site reactions (pain, redness, and bruising), upper respiratory infection, and headache.

These are not all the possible side effects of TAKHZYRO. For more information, ask your healthcare provider or pharmacist. You may report side effects to the FDA at 1–800–FDA–1088.

TAKHZYRO has not been studied in pregnant or breastfeeding women. Talk to your healthcare provider about the risk of taking TAKHZYRO if you are pregnant, plan to be pregnant, are breastfeeding, or plan to breastfeed.

Please see full Prescribing Information, including information for patients.